Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Variant CJD in plasma products

Executive Summary

FDA's Transmissible Spongiform Encephalopathies Advisory Committee will discuss risk assessments for potential exposure to variant Creutzfeldt-Jakob disease (vCJD) agent in plasma products at its Feb. 8 meeting. The committee will also consider possible vCJD risk from investigational coagulation Factor XI manufactured in the 1990s from plasma of donors residing in the U.K. and potential deferral of blood and plasma donors for history of transfusion in France and other European countries. The meeting will be held at the Hilton in Silver Spring, Md. at 8 a.m. [Editor's Note: To 1watch a webcastor order a video/DVD of this meeting, visit FDAAdvisoryCommittee.com]...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS045262

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel